A retrospective analysis of breast cancer based on outcome differences
- PMID: 1674493
- DOI: 10.1016/0046-8177(91)90134-b
A retrospective analysis of breast cancer based on outcome differences
Abstract
We reviewed tumors from two groups of patients with breast cancer, distinguished by differences in outcome. One group (85 cases) survived more than 8.5 years without tumor recurrence; the other 85 cases had recurrent disease within 2 years. Histologic and immunocytochemical studies on all cases were performed without patient identifiers and prior to review of clinical prognostic factors. As expected, lymph node and estrogen receptor status differed substantially between the groups, but menopausal status and family history for breast cancer did not. We noted that 27% of node-negative patients died within 5 years, and nine patients with four or more tumor-containing nodes were symptom-free for over 8.5 years. Histologic grade (degree of tubule formation) and nuclear grade (including mitotic rate) differed significantly between the groups, as did vascular invasion, including both lymphatics and blood vessels. Prognostic value attached to tumor border only when fat was invaded without fibroblastic or inflammatory response (P = .012). Subgrouping cases of infiltrating ductal carcinoma (not otherwise specified) was prognostically informative in the B subgroup, 69% of whom were in the rapidly recurrent tumor group. Immunocytochemical staining for c-erbB-2 was positive in 19.3% of cases, but was equally distributed between the two outcome groups. We conclude that traditional histologic parameters are highly informative, and that c-erbB-2 studies do not increase the value of histologic diagnosis.
Similar articles
-
p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.Am J Clin Pathol. 1992 Oct;98(4):408-18. doi: 10.1093/ajcp/98.4.408. Am J Clin Pathol. 1992. PMID: 1357956
-
Correlation of c-erbB-2 protein expression with histologic grade, lymph node involvement and steroid receptor status in human breast tumors.Arch Gynecol Obstet. 1992;251(1):45-50. doi: 10.1007/BF02718277. Arch Gynecol Obstet. 1992. PMID: 1347986
-
Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.Cancer Res. 1991 Jun 15;51(12):3296-303. Cancer Res. 1991. PMID: 1674898
-
Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.Pathol Oncol Res. 2015 Jul;21(3):553-61. doi: 10.1007/s12253-015-9944-5. Epub 2015 May 12. Pathol Oncol Res. 2015. PMID: 25962349 Review.
-
Inoperable recurrence after breast-conserving surgical treatment and radiotherapy.Surg Gynecol Obstet. 1991 May;172(5):357-61. Surg Gynecol Obstet. 1991. PMID: 1851336 Review.
Cited by
-
Bilateral breast cancer: one disease or two?Breast Cancer Res Treat. 1991 Nov;19(3):233-44. doi: 10.1007/BF01961160. Breast Cancer Res Treat. 1991. PMID: 1663803
-
High DNA content and prognosis in lymph node positive breast cancer. A case control study by the University of Leiden and ECOG. (Eastern Cooperative Oncology Group).Breast Cancer Res Treat. 1993 Oct;28(1):1-8. doi: 10.1007/BF00666350. Breast Cancer Res Treat. 1993. PMID: 8123866
-
Overexpression of mutant p53 and c-erbB-2 proteins and breast tumour take in mice.Br J Cancer. 1995 Nov;72(5):1160-4. doi: 10.1038/bjc.1995.480. Br J Cancer. 1995. PMID: 7577462 Free PMC article.
-
INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.Breast Cancer Res Treat. 1996;37(1):65-76. doi: 10.1007/BF01806633. Breast Cancer Res Treat. 1996. PMID: 8750529
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous